🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Spinal and Bulbar Muscular Atrophy

Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer NCT07260435Phase 326 sites📍 Alkmaar📍 Amersfoort📍 Amsterdam Nick Beije · Tests: ADT plus only 12 months of ARPI, ADT plus continued ARPI Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response NCT06592924Phase 3395 sites📍 Anchorage📍 Anchorage📍 Anchorage Canadian Cancer Trials Group · Tests: Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) NCT05404139Phase 22 sites📍 Toronto📍 Toronto University Health Network, Toronto · Tests: Abiraterone, Standard of Care SBRT and ADT, Atorvastatin Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer NCT07140900Phase 116 sites📍 San Francisco📍 Boston📍 Minneapolis Amgen · Tests: Xaluritamig, Darolutamide, Abiraterone Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma NCT06348264Phase 22 sites📍 Beijing📍 Beijing Peking University First Hospital · Tests: Rezvilutamide, Leuprolide Acetate Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer NCT04947189Phase 1, Phase 21 site📍 Darlinghurst St Vincent's Hospital, Sydney · Tests: Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel UK SMA Patient Registry NCT04292574n/a1 site📍 Newcastle upon Tyne Newcastle University · Tests: Patient Registry A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy NCT06169046Phase 21 site📍 Padova Gianni Soraru · Tests: Clenbuterol, Placebo Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response NCT07142551Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer NCT05095207Phase 1, Phase 23 sites📍 New York📍 New York📍 New York Icahn School of Medicine at Mount Sinai · Tests: Abemaciclib, Bicalutamide Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients NCT06473259n/a3 sites📍 Orbassano📍 Padova📍 Trento Santa Chiara Hospital · Tests: Docetaxel, Apalutamide Oral Tablet, Enzalutamide Oral Tablet, Abiraterone acetate tablets, Darolutamide Oral Tablet Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial NCT07650240Phase 21 site📍 Rochester Mayo Clinic · Tests: Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer NCT07832292Phase 25 sites📍 Lafayette📍 Plymouth📍 Syracuse Janssen Research & Development, LLC · Tests: JNJ-101556143 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health TherApeutics in Early ProState Cancer (TAPS02) NCT05191680Phase 26 sites📍 Cambridge📍 Bristol📍 Bury St Edmunds Cambridge University Hospitals NHS Foundation Trust · Tests: Apalutamide Oral Tablet [Erleada], Placebo High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe) NCT07223385Phase 21 site📍 Los Angeles Cedars-Sinai Medical Center · Tests: Cardio-Oncology Referral, Notification to PCP/General Cardiologist An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia NCT07223372n/a1 site📍 Pymble Bayer A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide NCT06844383Phase 28 sites📍 Duarte📍 La Jolla📍 Boston Prostate Cancer Clinical Trials Consortium · Tests: Talazoparib with enzalutamide, Talazoparib Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer NCT06705686Phase 11 site📍 Madison TechnoGenesys, Inc. · Tests: (R)-9bMS Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial NCT06378866Phase 23 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Abiraterone, Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity NCT04708431n/a1 site📍 Bethesda Eunice Kennedy Shriver National Institute of Child Health a… Study of ORIC-944 in Patients With Metastatic Prostate Cancer NCT05413421Phase 127 sites📍 Colorado Springs📍 Plantation📍 Arlington Heights ORIC Pharmaceuticals · Tests: ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darol… Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer NCT04946370Phase 1, Phase 24 sites📍 Boston📍 Brooklyn📍 New York Weill Medical College of Cornell University · Tests: 225Ac-J591, Pembrolizumab, Androgen receptor inhibitor, 68Ga-PSMA-11 START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC NCT05209243NA2 sites📍 Madrid📍 Valencia Instituto de Investigación en Oncología Radioterápica - Fun… · Tests: SBRT, STANDARD OF CARE Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer NCT07751133Phase 32 sites📍 Manchester📍 Sutton University College, London · Tests: Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer NCT06854250Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Prostate cryoablation, Cyclophosphamide (CTX) Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA) NCT04944940n/a1 site📍 Bethesda National Institute of Neurological Disorders and Stroke (NI… TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) NCT07190300Phase 1, Phase 231 sites📍 Birmingham📍 Iowa City📍 Westwood Novartis Pharmaceuticals · Tests: Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT) ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials NCT06141993n/a3 sites📍 New York📍 Durham📍 Madison Duke University ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) NCT04916613Phase 395 sites📍 Charleroi📍 Haine-Saint-Paul📍 Namur UNICANCER · Tests: Darolutamide 300 mg, Placebo, Androgen deprivation therapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy